| Theme | Progress in the management of phosphorus in chronic kidney disease | |
|---|---|---|
| Title | Progress in identification Pi transport inhibitors | |
| Publish Date | 2004/10 | |
| Author | Ken-ichi Miyamoto | Department of Molecular, Nutrition, Institution of Health Bioscience, The University of Tokushima Graduate School |
| Author | Hiroko Segawa | Department of Molecular, Nutrition, Institution of Health Bioscience, The University of Tokushima Graduate School |
| Author | Mikiko Ito | Department of Molecular, Nutrition, Institution of Health Bioscience, The University of Tokushima Graduate School |
| Author | Masashi Kuwahata | Department of Molecular, Nutrition, Institution of Health Bioscience, The University of Tokushima Graduate School |
| [ Summary ] | In 2003, the NKF K /DOQI released new clinical practice guidelines for bone metabolism and disease in chronic kidney disease, respectively. Target levels of phosphate and Ca X Pi products are set at relative low levels in the new guidelines. Prescription of a new phosphate binder, severamer hydrochloride, is widely recommended in this guideline. Other approaches that could prove fruitful include inhibition of intestinal and renal phosphate transporters. Inhibition of the sodium-dependent phosphate transporter by a small molecule would be a desirable method to control serum phosphate levels in patients with chronic renal disease or undergoning dialysis. In this review, progress in the identification of such an agent is discussed. | |